
Valeria De Nigris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4687247/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inflammageing and metaflammation: The yin and yang of type 2 diabetes. Ageing Research Reviews, 2018, 41, 1-17.	10.9	182
2	Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. Redox Biology, 2018, 15, 170-181.	9.0	102
3	"Inflammaging―as a Druggable Target: A Senescence-Associated Secretory Phenotype—Centered View of Type 2 Diabetes. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	4.0	93
4	The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report. Cardiovascular Diabetology, 2014, 13, 140.	6.8	58
5	The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Endocrine, 2017, 56, 509-520.	2.3	47
6	Short-term high glucose exposure impairs insulin signaling in endothelial cells. Cardiovascular Diabetology, 2015, 14, 114.	6.8	45
7	Novel insights into the regulation of miRNA transcriptional control: implications for T2D and related complications. Acta Diabetologica, 2018, 55, 989-998.	2.5	16
8	GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress. Therapeutics and Clinical Risk Management, 2015, 11, 901.	2.0	11
9	Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions. Oncotarget, 2018, 9, 8898-8910.	1.8	11
10	The pivotal role of high glucose-induced overexpression of PKCÎ ² in the appearance of glucagon-like peptide-1 resistance in endothelial cells. Endocrine, 2016, 54, 396-410.	2.3	10